Loading
The 2025 international consensus on early breast cancer, which recommends platinum chemotherapy and immunotherapy for triple-negative disease, updated genetic testing guidance and shorter radiotherapy schedules.
Consensus statement from the biennial St Gallen Breast Cancer Consensus conference by Burstein, Curigliano, Gnant, Loibl and colleagues. Innovations in 2025 include updated guidance on genetic testing; endorsement of hypofractionated and ultra-hypofractionated radiotherapy for more patients; a recommendation for platinum-based chemotherapy in triple-negative breast cancer and use of biological risk markers to consider anthracyclines in other subtypes; avoidance of sentinel lymph node surgery in many low-risk oestrogen receptor-positive cancers; use of immunotherapy in triple-negative and certain oestrogen receptor low-positive tumours; guidance on re-irradiation and systemic therapy at locoregional recurrence; criteria for oligometastatic disease; and survivorship recommendations on neuropathy and sexual health.
Platinum and immunotherapy are now consensus for early triple-negative disease; the open votes have moved to who can safely receive less.
Shares Giuseppe Curigliano, Sibylle Loibl, De-escalation, escalation and response-adapted therapy, Annals of Oncology and the tag tnbc-evidence.
Shares Sibylle Loibl, KEYNOTE-522, Annals of Oncology, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Pembrolizumab, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Giuseppe Curigliano, Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares KEYNOTE-522, Annals of Oncology, Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Platinum agents, Carboplatin and the tag tnbc-evidence.
Shares Annals of Oncology, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Platinum agents, Carboplatin and the tag tnbc-evidence.